Exicure, Inc. (Nasdaq: XCUR) today announced that it has entered into a co-development agreement with Adbiotech Co., Ltd. (KOSDAQ: 179530), a Korea-based biotechnology company, to explore combination ...
Medically integrated dispensing improves affordability, adherence, and toxicity management via embedded pharmacy teams, ...
There is new research happening at Roswell Park Comprehensive Cancer Center to see if CAR T-cell therapy that has worked for ...
Patients with hematologic malignancies face significantly higher short- and long-term risk for cardiovascular disease vs the general public.
Patients dosed in Phase 1 safety and tolerability study of MDX2003, a novel T-cell engager designed to optimize killing of lymphomasPreclinical ...
Disc Medicine advances therapies for serious blood disorders; a key insider recently trimmed their stake amid strong one-year share gains.
The CAR-PRISM trial enrolled patients with high-risk smoldering multiple myeloma as defined by the 20/2/20 model: plasma ...
Zacks Investment Research on MSN
Bristol Myers vs Gilead Sciences: Which biotech stock is a better bet now?
Bristol Myers Squibb BMY and Gilead Sciences GILD are two leading biotech players with diversified portfolios and a strong ...
Disc Medicine, Inc. (NASDAQ:IRON), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for patients suffering from serious ...
Chronic oral glucocorticoid use is linked to increased mortality, with risk rising alongside higher cumulative exposure and daily doses.
SAN DIEGO -- Half of heavily pretreated patients with platinum-refractory ovarian cancer (PROC) responded to an ...
"We need effective anti-bias interventions to improve care for patients with sickle cell disease, and this deeper understanding is a step in the right direction," said the study author.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results